JPMorgan raised the firm’s price target on Elevance Health (ELV) to $397 from $394 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target lowered to $409 from $431 at Bernstein
- Elevance Health price target lowered to $391 from $424 at Wells Fargo
- Elevance Health price target lowered to $393 from $404 at Barclays
- Elevance Health price target lowered to $400 from $425 at UBS
- Elevance Health price target raised to $332 from $320 at Deutsche Bank